Production (Stage)
Madrigal Pharmaceuticals, Inc.
MDGL
$278.23
$4.131.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 32.84% | 66.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 32.84% | 66.18% | |||
| Cost of Revenue | 31.00% | 60.08% | |||
| Gross Profit | 32.90% | 66.39% | |||
| SG&A Expenses | 18.87% | 31.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.15% | -4.57% | |||
| Operating Income | -18.38% | 42.40% | |||
| Income Before Tax | -23.26% | 44.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.26% | 44.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.26% | 44.45% | |||
| EBIT | -18.38% | 42.40% | |||
| EBITDA | -18.46% | 42.56% | |||
| EPS Basic | -22.36% | 44.92% | |||
| Normalized Basic EPS | -22.36% | 44.92% | |||
| EPS Diluted | -22.36% | 44.92% | |||
| Normalized Diluted EPS | -22.36% | 44.92% | |||
| Average Basic Shares Outstanding | 0.74% | 0.84% | |||
| Average Diluted Shares Outstanding | 0.74% | 0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||